Aktienanalyse zu Assembly Biosciences Inc (ASMB)ASMBAssembly Biosciences Inc

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Assembly Biosciences Inc is a good buy right now due to its current price of $34.07, which is significantly below analyst price targets of $43 and $45, indicating potential upside of 26% to 32%. Additionally, the company reported a strong revenue growth of 153.5% year-over-year, reaching $72.3 million, which reflects robust demand for its products. The main risk is the negative earnings per share (EPS) of -0.20 reported recently, indicating ongoing losses, but the strong cash position of $248.1 million suggests it can fund operations into 2028, mitigating immediate financial concerns.